LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

• Main Authors: Tamer Coskun (Author), Kyle W. Sloop (Author), Corina Loghin (Author), Jorge Alsina-Fernandez (Author), Shweta Urva (Author), Krister B. Bokvist (Author), Xuewei Cui (Author), Daniel A. Briere (Author), Over Cabrera (Author), William C. Roell (Author), Uma Kuchibhotla (Author), Julie S. Moyers (Author), Charles T. Benson (Author), Ruth E. Gimeno (Author), David A. D'Alessio (Author), Axel Haupt (Author)
• Format: Book
• Published: Elsevier, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). Methods: LY3298176 is a fatty acid modified peptide wit...